Erratum: ADRA1A gene is associated with BMI in chronic schizophrenia patients exposed to antipsychotics (The Pharmacogenomics Journal (2010) 10, (30-39) DOI: 10.1038/tpj.2009.55);ADRA1A gene is associated with BMI in chronic schizophrenia patients exposed to antipsychotics

Pharmacogenomics Journal

Volumn 10, Issue 1, 2010, Pages 30-39

  Liu, Y R ^a,b   Loh, E W ^a   Lan, T H ^a,c,d   Chen, S F ^e   Yu, Y H ^c   Chang, Y H ^a,c   Huang, C J ^f   Hu, T M ^g   Lin, K M ^a   Yao, Y T ^b   Chiu, H J ^h  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^f NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^g YULI VETERANS HOSPITAL   (Taiwan)

^h Jianan Mental Hospital   (Taiwan)

Author keywords

ADR; ADRA1A gene; Antipsychotics; BMI; Obesity; Schizophrenia

Indexed keywords

ALPHA 1A ADRENERGIC RECEPTOR; ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; DNA DETERMINATION; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; SCHIZOPHRENIA; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; WEIGHT GAIN;

EID: 75549092068     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2011.39     Document Type: Erratum

References (63)

1. Aronne LJ. Epidemiology, morbidity, and treatment of overweight and obesity. J Clin Psychiatry 2001; 62(Suppl 23): 13-22.
2. Hsiao CC, Ree SC, Chiang YL, Yeh SS, Chen CK. Obesity in schizophrenic outpatients receiving antipsychotics in Taiwan. Psychiatry Clin Neurosci 2004; 58: 403-409.
3. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007; 68(Suppl 1): 20-27.
4. Reinholz J, Skopp O, Breitenstein C, Bohr I, Winterhoff H, Knecht S. Compensatory weight gain due to dopaminergic hypofunction: new evidence and own incidental observations. Nutr Metab (Lond) 2008; 5: 35.
5. Leibowitz SF, Alexander JT. Hypothalamic serotonin in control of eating behavior, meal size, and body weight. Biol Psychiatry 1998; 44: 851-864.
6. Templeman L A, Reynolds G P, Arranz B, San L. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first episode psychosis. Pharmacogenet Genomics 2005; 15: 195-200.
7. Correll CU, Malhotra AK. Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology (Berl) 2004; 174: 477-489.
8. Müller DJ, Muglia P, Fortune T, Kennedy JL. Pharmacogenetics of antipsychotic-induced weight gain. Pharmacol Res 2004; 49: 309-329.
9. Chagnon YC. Susceptibility genes for the side effect of antipsychotics on body weight and obesity. Curr Drug Targets 2006; 7: 1681-1695.
10. Bray GA. Obesity, a disorder of nutrient partitioning: the MONA LISA hypothesis. J Nutr 1991; 121: 1146-1162.
11. Fain JN, Garcija-Sainz JA. Adrenergic regulation of adipocyte metabolism. J Lipid Res 1983; 24: 945-966.
12. Knowler WC, Pettitt DJ, Saad MF, Charles MA, Nelson RG, Howard BV et al. Obesity in the Pima Indians: its magnitude and relationship with diabetes. Am J Clin Nutr 1991; 53: 1543S-1551S.
13. Snitker S, Tataranni PA, Ravussin E. Respiratory quotient is inversely associated with muscle sympathetic nerve activity. J Clin Endocrinol Metab 1998; 83: 3977-3979.
14. Bai YM, Lin CC, Chen JY, Lin CY, Su TP, Chou P. Association of initial antipsychotic response to clozapine and long-term weight gain. Am J Psychiatry 2006; 163: 1276-1279.
15. Procyshyn RM, Wasan KM, Thornton AE, Barr AM, Chen EY, Pomarol-Clotet E et al. Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. J Psychiatry Neurosci 2007; 32: 331-338.
16. Nonogaki K. New insights into sympathetic regulation of glucose and fat metabolism. Diabetologia 2000; 43: 533-549.
17. Piascik MT, Perez DM. Alpha1-adrenergic receptors: new insights and directions. J Pharmacol Exp Ther 2001; 298: 403-410.
18. Phares DA, Halverstadt AA, Shuldiner AR, Ferrell RE, Douglass LW, Ryan AS et al. Association between body fat response to exercise training and multilocus ADR genotypes. Obes Res 2004; 12: 807-815.
19. Dionne IJ, Turner AN, Tchernof A, Pollin TI, Avrithi D, Gray D et al. Identification of an interactive effect of beta3-and alpha2b-adreno-ceptor gene polymorphisms on fat mass in Caucasian women. Diabetes 2001; 50: 91-95.
20. Linne Y, Dahlman I, Hoffstedt J. Beta1-adrenoceptor gene polymorphism predicts long-term changes in body weight. Int J Obes Relat Metab Disord 2005; 29: 458-462.
21. Dionne IJ, Garant MJ, Nolan AA, Pollin TI, Lewis DG, Shuldiner AR et al. Association between obesity and a polymorphism in the beta(1)-adrenoceptor gene (Gly389Arg ADRB1) in Caucasian women. Int J Obes Relat Metab Disord 2002; 26: 633-639.
22. Lin RCY, Ericsson JO, Benjafield AV, Morris BJ. Association of beta2-adrenoceptor Gln27Glu variant with body weight but not hypertension. Am J Hypertens 2001; 14: 1201-1204.
23. Pereira AC, Floriano MS, Mota GF, Cunha RS, Herkenhoff FL, Mill JG et al. Beta2 adrenoceptor functional gene variants, obesity, and blood pressure level interactions in the general population. Hypertension 2003; 42: 685-692.
24. Ehrenborg E, Skogsberg J, Ruotolo G, Large V, Eriksson P, Arner P et al. The Q/E27 polymorphism in the beta2-adrenoceptor gene is associated with increased body weight and dyslipoproteinaemia involving trigly-ceride-rich lipoproteins. J Intern Med 2000; 247: 651-656.
25. Martinez JA, Corbalan MS, Sanchez-Villegas A, Forga L, Marti A, Martinez-Gonzalez MA. Obesity risk is associated with carbohydrate intake in women carrying the Gln27Glu beta2-adrenoceptor polymorphism. J Nutr 2003; 133: 2549-2554.
26. Macho-Azcarate T, Marti A, Calabuig J, Martinez JA. Basal fat oxidation and after a peak oxygen consumption test in obese women with a beta2 adrenoceptor gene polymorphism. J Nutr Biochem 2003; 14: 275-279.
27. Meirhaeghe A, Helbecque N, Cottel D, Amouyel P. Impact of polymorphisms of the human beta2-adrenoceptor gene on obesity in a French population. Int J Obes Relat Metab Disord 2000; 24: 382-387.
28. Ukkola O, Perusse L, Chagnon YC, Despres JP, Bouchard C. Interactions among the glucocorticoid receptor, lipoprotein lipase and adrenergic receptor genes and abdominal fat in the Quebec Family Study. Int J Obes Relat Metab Disord 2001; 25: 1332-1339. (Pubitemid 32835451)
29. Gonzalez Sanchez JL, Proenza AM, Martinez Larrad MT, Ramis JM, Fernandez PC, Palou A et al. The glutamine 27 glutamic acid polymorphism of the beta2-adrenoceptor gene is associated with abdominal obesity and greater risk of impaired glucose tolerance in men but not in women: a population-based study in Spain. Clin Endocrinol (Oxf) 2003; 59: 476-481.
30. Ochoa MC, Marti A, Azcona C, Chueca M, Oyarzabal M, Pelach R et al. Gene-gene interaction between PPAR gamma 2 and ADR beta 3 increases obesity risk in children and adolescents. Int J Obes Relat Metab Disord 2004; 28(Suppl 3): S37-S41.
31. Xinli W, Xiaomei T, Meihua P, Song L. Association of a mutation in the beta3-adrenergic receptor gene with obesity and response to dietary intervention in Chinese children. Acta Paediatr 2001; 90: 1233-1237.
32. Baldessarini RJ, Huston-Lyons D, Campbell A, Marsh E, Cohen BM. Do central antiadrenergic actions contribute to the atypical properties of clozapine? Br J Psychiatry Suppl 1992; 17: 12-16.
33. Clark DA, Arranz MJ, Mata I, Lopez-Ilundain J, Perez-Nievas F, Kerwin RW. Polymorphisms in the promoter region of the alpha1A-adrenoceptor gene are associated with schizophrenia/schizoaffective disorder in a Spanish isolate population. Biol Psychiatry 2005; 58: 435-439.
34. Huang K, Shi Y, Tang W, Tang R, Guo S, Xu Y et al. No association found between the promoter variants of ADRA1A and schizophrenia in the Chinese population. J Psychiatr Res 2008; 42: 384-388. (Pubitemid 351253573)
35. Basile VS, Masellis M, McIntyre RS, Meltzer HY, Lieberman JA, Kennedy JL. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry 2001; 62(Suppl 23): 45-66.
36. Ujike H, Nomura A, Morita Y, Morio A, Okahisa Y, Kotaka T et al. Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study. J Clin Psychiatry 2008; 69: 1416-1422.
37. Okajima Y, Togo M, Kitagawa G, Nishikawa S. Time series analysis of monthly body weight and blood pressures of one man from 29-65 years. Am J Human Biol 2000; 12: 526-541.
38. Simondon KB, Ndiaye T, Dia M, Yam A, Ndiaye M, Marra A et al. Seasonal variations and trends in weight and arm circumference of non-pregnant rural Senegalese women, 1990-1997. Eur J Clin Nutr 2008; 62: 997-1004.
39. Yang M, Leung SS. Weight and length growth of two Chinese infant groups and the seasonal effects on their growth. Ann Hum Biol 1994; 21: 547-562.
40. Lei B, Morris DP, Smith MP, Svetkey LP, Newman MF, Rotter JI et al. Novel human alpha1a-adrenoceptor single nucleotide polymorphisms alter receptor pharmacology and biological function. Naunyn Schmiede-bergs Arch Pharmacol 2005; 371: 229-239.
41. Razik MA, Lee K, Price RR, Williams MR, Ongjoco RR, Dole MK et al. Transcriptional regulation of the human alpha1a-adrenergic receptor gene. Characterization of the 5'-regulatory and promoter region. J Biol Chem 1997; 272: 28237-28246.
42. Tebbutt SJ. Genotyping of single nucleotide polymorphisms by arrayed primer extension. Methods Mol Biol 2007; 382: 149-161.
43. Pan WH, Yeh WT. How to define obesity? Evidence-based multiple action points for public awareness, screening, and treatment: an extension of Asian-Pacific recommendations. Asia Pac J Clin Nutr 2008; 17: 370-374.
44. Tadger S, Melamed Y. Weight gain due to long term antipsycho-tic treatment of persistent mental disorders. Psychiatr Danub 2008; 20: 37-41.
45. Shibata K, Hirasawa A, Moriyama N, Kawabe K, Ogawa S, Tsujimoto G. Alpha 1a-adrenoceptor polymorphism: pharmacological characterization and association with benign prostatic hypertrophy. Br J Pharmacol 1996; 118: 1403-1408.
46. Bolonna AA, Arranz MJ, Munro J, Osborne S, Petouni M, Martinez M et al. No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response. Neurosci Lett 2000; 280: 65-68.
47. Woodcock EA, Wang BH, Arthur JF, Lennard A, Matkovich SJ, Du XJ et al. Inositol polyphosphate 1-phosphatase is a novel antihypertrophic factor. J Biol Chem 2002; 277: 22734-22742.
48. Clark DA, Mancama D, Kerwin RW, Arranz MJ. Expression of the alpha1A-adrenergic receptor in schizophrenia. Neurosci Lett 2006; 401: 248-251.
49. Li LM, Lei SF, Chen XD, Deng FY, Tan LJ, Zhu XZ et al. Anthropometric indices as the predictors of trunk obesity in Chinese young adults: receiver operating characteristic analyses. Ann Hum Biol 2008; 35: 342-348.
50. Lee CM, Huxley RR, Wildman RP, Woodward M. Indices of abdominal obesity are better discriminators of cardiovascular risk factors than BMI: a meta-analysis. J Clin Epidemiol 2008; 61: 646-653.
51. Romero R, Bonet J, de la Sierra A, Aguilera MT. Undiagnosed obesity in hypertension: clinical and therapeutic implications. Blood Press 2007; 16: 347-353.
52. Buckley NA, Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drug Saf 2000; 23: 215-228.
53. Nourian Z, Mow T, Muftic D, Burek S, Pedersen ML, Matz J et al. Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of alpha1-adrenoceptor function. Psychophar-macology (Berl) 2008; 199: 15-27.
54. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000; 68: 29-39.
55. Sramek JJ, Mack RJ, Awni W, Hourani J, Jhee SS, Barto S et al. Two rapid-dose titrations of sertindole in patients with schizophrenia. J Clin Psychopharmacol 1997; 17: 419-422.
56. Barnes TR, McPhillips MA. Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics. Br J Psychiatry Suppl 1999; 38: 34-43.
57. Gu D, Ge D, Snieder H, He J, Chen S, Huang J et al. Association of alpha1A adrenergic receptor gene variants on chromosome 8p21 with human stage 2 hypertension. J Hypertens 2006; 24: 1049-1056.
58. Landsberg L, Young JB. Catecholamines and the adrenal medulla. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR (eds). Williams Textbook of Endocrinology, 9th edn Saunders: Philadelphia, 1992 pp 621-706.
59. Zahorska-Markiewicz B, Kucio C, Piskorska D. Adrenergic control of lipolysis and metabolic responses in obesity. Horm Metab Res 1986; 18: 693-697.
60. DeFronzo RA, Thorin D, Felber JP, Simonson DC, Thiebaud D, Jequier et al. Effect of beta and alpha adrenergic blockade on glucose-induced thermogenesis in man. J Clin Invest 1984; 73: 633-639.
61. Faintrenie G, Geloen A. Alpha-1 adrenergic stimulation of glucose uptake in rat white adipocytes. J Pharmacol Exp Ther 1998; 286: 607-610.
62. Boschmann M, Krupp G, Luft FC, Klaus S, Jordan J. In vivo response to alpha(1)-adrenoreceptor stimulation in human white adipose tissue. Obes Res 2002; 10: 555-558. (Pubitemid 135686649)
63. Flechtner-Mors M, Jenkinson CP, Alt A, Adler G, Ditschuneit HH. In vivo alpha(1)-adrenergic lipolytic activity in subcutaneous adipose tissue of obese subjects. J Pharmacol Exp Ther 2002; 301: 229-233.